Security News
Spotlight On: Prolia® / Xgeva® (denosumab) / Jubbonti® / Wyost® (denosumab-bbdz) / Ospomyv® / Xbryk® (denosumab-dssb) / Stoboclo® / Osenvelt® (denosumab-bmwo) / Conexxence™ / Bomyntra™ (denosumab-bnht) / Bildyos® / Bilprevda® (denosumab-nxxp) / Bosaya™ / Aukelso™ (denosumab-kyqq) / Enoby™ / Xtrenbo™ (denosumab-qbde) / Osvyrti® / Jubereq® (denosumab-desu) / Boncresa™ / Oziltus™ (denosumab-mobz) / Ponlimsi™ (denosumab-adet) - April 2026
UnknownApr 17, 2026(23 days ago)
The article discusses claim types challenged in litigation related to Denosumab, analyzed by Venable LLP.
Denosumab Challenged Claim Types in Litigation: Claims are counted in each litigation, so claims from the same patent challenged in multiple litigations are counted more than once. Within each litigation a claim is counted only once. Claims in litigations are determined based on claims alleged to be infringed or invalid in Complaints.... By: Venable LLP